At Celgene, we assess the value of our innovative medicines over the long term, with a clearly defined, holistic approach. The goal of our approach to value is the creation of a virtuous cycle in which access to therapies today drives future innovation.
We believe that the value of innovation extends beyond just the patients who are the direct beneficiaries of our medicines. We therefore define value across the following four pillars:
No other sector of the economy touches people and society as broadly as healthcare, which is why any assessment of healthcare costs, and the associated value, must be holistic and multi-dimensional. Value in healthcare lies at the intersection of costs and the related benefits to patients, the health system, society and economy, and the future of innovation; viewing one without considering the other elements risks potentially shortsighted decisions that undervalue innovative therapies that doctors and patients so badly need. Celgene continues to adhere to our Principles for the Pricing of Innovative Medicines and we are working collaboratively with governments, health systems, payors and other stakeholders to find constructive solutions to enhance patient health and access.
Throughout this page you will see Celgene’s perspective on value transparency, value assessments, as well as facts and data on drug pricing and patient access. It also includes resources that highlight advancements being made in cancers such as multiple myeloma, lymphoma and breast cancer as well as immune and inflammatory diseases including multiple sclerosis and psoriasis. At Celgene, we believe in the virtuous cycle of innovation: the idea that the success of today’s treatments allows us to invest in tomorrow’s breakthroughs.
patients around the world treated with Celgene medicines in 2018.
patients have received support from Celgene, including disease education and health system navigation.
compounds in the Celgene library with potential applications for treating neglected Diseases of the Developing World (DDW)
patients enrolled in Celgene-sponsored studies
total jobs in the U.S. supported by the biopharmaceutical industry
researchers added to the Celgene workforce over the last ten years
invested in R&D in 2018
of Celgene revenues reinvested in R&D in 2018
Multiple sclerosis is a complex disease. The toll on patients, society and the healthcare system is substantial, but innovative therapies can hold promise and opportunity to address these unmet needs, potentially delivering new benefits for patients.